Xenon Pharmaceuticals Inc.
XENE
$37.11
-$0.40-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -278.23M | -251.45M | -234.33M | -213.39M | -199.06M |
| Total Depreciation and Amortization | 2.59M | 2.60M | 2.53M | 1.27M | 2.33M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 52.51M | 51.63M | 43.81M | 45.55M | 35.62M |
| Change in Net Operating Assets | -8.29M | -1.12M | 5.12M | 2.68M | 294.00K |
| Cash from Operations | -231.42M | -198.34M | -182.87M | -163.89M | -160.82M |
| Capital Expenditure | -1.57M | -2.93M | -3.08M | -2.37M | -2.98M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 218.83M | 247.12M | 169.56M | -169.44M | -116.93M |
| Cash from Investing | 217.25M | 244.19M | 166.48M | -171.81M | -119.91M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.35M | 13.28M | 12.13M | 324.01M | 353.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13.35M | 13.28M | 12.13M | 324.01M | 353.52M |
| Foreign Exchange rate Adjustments | -535.00K | -1.37M | -1.67M | -269.00K | -611.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.35M | 57.76M | -5.93M | -11.95M | 72.18M |